entertainment -WSS

entertainment

author：Wikipedia 2025-09-03 15:16:54 - browse：123

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Secretariat’s lessons for human medicine

knowledge

WSS

Malaysia cuts short music fest after British band slams anti

FDA warns medical device makers about rise in fabricated data

FDA warns medical device makers about rise in fabricated data

Surprise medical billing ban raises prices elsewhere

As AI regulations shape up, health tech startups beg for clarity

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

hotspot

entertainment

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Peter Hotez and the public health issue of online harassment

Burning questions about Delta and the next phase of the Covid pandemic

Virginia high school admissions case could be legal follow

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Novavax promises a turnaround & Lilly roils the obesity market

New study raises questions about niacin and heart health

Anesthesiologist group: stop taking Ozempic before surgery

A new drug could help frostbite victims avoid its ravages

hotspot

FDA approves first blood sugar monitor without finger pricks

Hospitals are piloting generative AI tools as regulators play catch

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Doctors have an ethical obligation to be advocates

Researchers tackle phage therapy hurdles for wider adoption

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

knowledge

hotspot

leisure time

hotspot